Product logins

Find logins to all Clarivate products below.


Schizophrenia – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of schizophrenia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s schizophrenia forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of schizophrenia and the number of new diagnoses of schizophrenia?
  • Of all people diagnosed with schizophrenia, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of schizophrenia over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following schizophrenia subpopulations:

  • Diagnosed incident cases.
  • Diagnosed prevalent cases by symptom status.
  • Diagnosed prevalent cases by comorbidity scheme.
  • Diagnosed prevalent cases by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Landscape & Forecast – Disease Landscape & Forecast (G7)
The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of generic drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Ocular Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Schizophrenia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Schizophrenia (US)
Schizophrenia is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…